Keros <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Initiates Phase 3 Clinical Trial for Elritercept, Triggers $10 Million Milestone Payment
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, has commenced the Phase 3 RENEW clinical trial involving elritercept. This trial focuses on adults with transfusion-dependent anemia associated with very low, low, or intermediate risk myelodysplastic syndromes (MDS). The first patient dosing in this trial has triggered a $10 million milestone payment to Keros from Takeda, under a global license agreement. This agreement, effective since January 2025, allows Takeda to develop, manufacture, and commercialize elritercept outside of mainland China, Hong Kong, and Macau. Keros had previously received a $200 million upfront cash payment and is eligible for additional development, commercial, and sales milestones that could exceed $1.1 billion. Additionally, Keros will be entitled to tiered royalties on net sales. The results of this trial are yet to be presented.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001664710-25-000062), on July 17, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.